Using Big Data to make Better Decisions in Healthcare - Diaceutics
+

Presentation Summary
Of the 1.37 million patients diagnosed with metastatic lung cancer in 2019, only 9,873 of them will have a NTRK gene fusion and be eligible for a targeted therapy that will likely have a significant impact on their quality of life. A lung cancer specialist in the US will only encounter 1 of these patients every 3 years. Through the course of this presentation, we are going to find those patients and save their lives.

About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

Latest Blogs

Latest Blogs